Jefferies downgraded Deciphera to Hold from Buy with a price target of $25.60, down from $26, after Ono agreed to acquire Deciphera for $25.60 per share in cash. The firm expects the deal to close by Q3, since Ono’s broad cancer pipeline is synergistic and has no real overlap with Deciphera, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential